Periodontal Disease Preceding Osteonecrosis of the Jaw in Cancer Patients Treated with Antiresorptives

2015    In September, 2014, The European Society for Medical Oncology (ESMO) published clinical practice guidelines for maintaining bone health in patients with cancer. The guidelines address both multidisciplinary treatments for reducing skeletal effects of metastatic disease and strategies for minimizing treatment-induced skeletal damage. The guidelines article was published in the Annals of Oncology by R. Coleman, J. J. Body, M. Aapro, P. Hadji, and J. Herrstedt on behalf of the ESMO Guidelines Working Group.*

Read More

Integration of Oncology and Palliative Care Programs: An International Consensus

Many national and international professional organizations have called for increased integration of oncology and palliative care in order to meet the supportive care needs of cancer patients, but to date, there has been a lack of a global consensus on an acceptable level of integration of oncology and palliative care. Study Group members initiated a Delphi survey (three iterations) to develop an international consensus on indicators for the integration of specialty palliative care and oncology programs for hospitalized advanced cancer patients. Respondents, mostly from North America and Europe, reached consensus on 13 major and 30 minor indicators. Major indicators were related to clinical structure (e.g., presence of palliative care inpatient team), processes (e.g., early palliative care referral), outcomes (e.g., median time from diagnosis to palliative care consultation), and education (e.g., routine rotation of oncology fellows to palliative care). The indicators can be used to identify centers with a high level of integration and to facilitate benchmarking, quality improvement, and research.

Read More

MASCC/ESMO Antiemetic Guidelines Update

2016    The MASCC/ESMO Antiemetic Guidelines have been updated as of March, 2016. The guidelines are based on the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015, and have been endorsed by both MASCC and ESMO. This set of evidence-based guidelines represents several important changes and first-time inclusions. This is the first time that recommendations about management of nausea and vomiting in advanced cancer have been included — as opposed to only nausea and vomiting induced by chemotherapy or radiotherapy — and in this respect, the new MASCC/ESMO guidelines differ from those of NCCN and ASCO. The new guidelines contain recommendations for two new NK1 receptor antagonists, rolapitant and netupitant, the latter given in combination with palonosetron (NEPA), and also discuss the use of olanzapine. The combination of an anthracycline with cyclophosphamide, previously considered of medium emetogenic risk (30-90% risk of vomiting) is now considered a high-risk combination (>90% risk of vomiting). However, this remains a special case, since recommendations for the delayed phase differ from those of other chemotherapies of highly emetogenic risk. In addition, carboplatin is now considered a special case with an indication for triple preventative therapy in the acute phase.

Read More

fda-approves-single-dose-fosaprepitant

2016    In February, 2016, the US Food and Drug Administration approved a single-use injection of fosaprepitant dimeglumine (Emend®) to prevent delayed nausea and vomiting in adults receiving an initial or repeat course of moderately emetogenic chemotherapy. The drug was already approved for highly emetogenic chemotherapy. The approval was based in part on a phase III trial comparing a single IV infusion (150 mg) of fosaprepitant dimeglumine in combination with ondansetron and dexamethasone with a control regimen ondansetron and dexamethasone alone. 

Read More

FDA Approves Rolapitant for Chemotherapy-Induced Nausea and Vomiting

2015    On September 2, 2015, the US Food and Drug Administration (FDA) approved rolapitant (Varubi™) for the prevention of chemotherapy-induced nausea and vomiting (CINV). Rolapitant, developed by Tesaro, Inc., is a selective and competitive neurokinin 1 (NK-1) receptor antagonist and is relatively long-acting with a half-life of about 7 days). The approval was based on three phase III clinical trials conducted by a research team that included MASCC members Bernardo Rapoport, Martin Chasen, Allen Poma, Lee Schwartzberg, and Rudolph Navari. These randomized, double-blind, controlled trials established the safety and efficacy of rolapitant. The drug was associated with a significant reduction in vomiting and use of rescue antiemetic drugs. Patients treated with rolapitant also reported both fewer episodes of nausea that interfered with their day-to-day life.

Read More

Cancer-Related Fatigue and Supportive Care

2015    Cancer-related fatigue is a common symptom that significantly affects quality of life and is one with physical, emotional, and cognitive components. Fatigue can be a direct effect of cancer itself or of cancer treatments, such as chemotherapy or radiotherapy, following which it is often a long-term problem. Many patients are not prepared for the degree of fatigue they might experience after treatment and/or not educated in management strategies to cope with it, even though a number of interventions have been found helpful. These include exercise, diet, adequate sleep, education, information, counseling, and complementary therapies.

Read More

Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Survivors

2015    It is well known that chemotherapy-induced symptoms, including peripheral neuropathy, often lead to the reduction or premature discontinuation of drug dosages in a large proportion of patients. This can mean that patients receive significantly less chemotherapy. The taxanes, paclitaxel and docetaxel, are one class of chemotherapeutic drugs with this effect.

Read More

Supportive Care in Lung Cancer: The Past 40 Years

2015    The year 2014 marked the 40th anniversary of the International Association of the Study of Lung Cancer (IASLC), a global organization that works to enhance the understanding of lung cancer among scientists, members of the medical community, and the public.* MASCC and IASLC frequently collaborate to address the challenges of lung cancer, its symptoms, including cough and breathlessness, and their management. The new MASCC Respiratory Study Group has identified breathlessness as its first priority for developing evidence-based guidelines.

Read More

Predicting Diarrhea and Rash in Breast Cancer Patients Treated with Lapatinib and Capecitabine

2015    MASCC Skin Toxicity Study Group Co-Chair Mario Lacouture has collaborated with Dr. George Dranitsaris of Augmentium Pharma Consulting in Toronto, Ontario, on the development of models for predicting the risks of diarrhea and rash in breast cancer patients being treated with lapatnib and capecitabine.

Read More

MASCC/ISOO Clinical Practice Guidelines for Management of Mucositis Included in the National Guideline Clearinghouse

2014    The MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy are now included in the National Guideline Clearinghouse™ (NGC). The NGC is a database of evidence-based clinical practice guidelines and related documents, maintained as a public resource by the US Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services. Inclusion in the NGC is contingent on meeting rigorous criteria, including evidence of a systematic literature review, systematically developed recommendations for optimal care in specific clinical circumstances, and an assessment of the benefits and harms of recommended care. The NGC carries the latest update of MASCC Mucositis Guidelines, published by Rajesh Lalla et al in Cancer in May, 2014 (open access).

Read More

Dr. Ian Olver presented an evaluation of a Digital Clinical Practice Guidelines Project undertaken by Cancer Council Australia

2013    At the MASCC/ISOO 2013 International Cancer Care Symposium in Berlin, Dr. Ian Olver presented an evaluation of a Digital Clinical Practice Guidelines Project undertaken by Cancer Council Australia, of which he is Chief Executive Officer.

Read More

MASCC/ISOO Study Group Chairs Lead Study on Oral Complications of Radiotherapy

2012    Carolinas HealthCare System (CHS) Receives $8 Million NIH Grant to Conduct First-Ever Study of its Kind. CHS’s Carolinas Medical Center has been awarded an $8 million grant from the National Institute of Dental and Craniofacial Research (NIDCR) to study dental and oral medicine outcomes of patients who have received high-dose radiation to the head and neck region. This is the largest research grant ever awarded to CHS. As the awardee organization, CHS will administer the grant, which will be shared across the several sites involved in the study. Each year 40,000 Americans develop head and neck cancer, and many have to receive high-dose radiation therapy, often in combination with surgery and/or chemotherapy. An unavoidable side effect of radiation therapy is damage to the oral and maxillofacial tissues, some of which persist for the lifetime of the patient.

Read More

Diagnostic and Management Practices for Oral Chronic Graft-Versus-Host Disease (cGVHD)

2012    The Oral Care Study Group conducted a study on the diagnosis and treatment of oral chronic graft-versus-host disease (cGVHD). The study was designed to assess common practices, as well as to determine use of the National Institute of Health scale for the diagnosis and grading of oral cGVHD. The project was headed by Sharon Elad, DMD, MSc, Eastman Institute for Oral Health, University of Rochester Medical Center.

Read More

ESMO Group Room Interview with Keefe 2010

2010    The Group Room at the 35th European Society for Medical Oncology Congress in Milan, Italy, was the debut of our full video format in Europe and is now available for viewing and posting. Watch all of this year's special feature interviews here. You can also watch these videos and more on the Vital Options YouTube Channel.

Read More